About: American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 1

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 1 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 1
Creator	David, ; Downes, Kevin Karp, R Mudano, Amy Turner, Amy Ardoin, P Columbus, Jones Cpnp, Karla Laxer, Ronald Lo, Mindy Madan, Pellet Mehta, Jay Rebecca, ; Ringold, Sarah Rubinstein, Tamar Stacy, ; Wahezi, Dawn
Source	Medline; PMC
abstract	OBJECTIVE: To provide clinical guidance to rheumatology providers who treat children with PRD in the context of the COVID‐19 pandemic. METHODS: The task force, consisting of 7 pediatric rheumatologists, 2 pediatric infectious disease physicians, one adult rheumatologist and one pediatric nurse practitioner, was convened on May 21, 2020. Clinical questions and subsequent guidance statements were drafted based on review of queries posed by patients, families and healthcare providers of children with PRD. An evidence report was generated and disseminated to task force members to assist with three rounds of asynchronous, anonymous voting by email using a modified Delphi approach. Voting was completed using a 9‐point numeric scoring system with predefined levels of agreement (“disagreement”; “uncertain”; “agreement”) and consensus. To be approved as a guidance statement, median votes were required to fall into the highest tertile for agreement with “moderate” (M) or “high” (H) levels of consensus. RESULTS: 33 guidance statements were drafted and voted upon during rounds two and three of voting. Of these statements, all received median votes within the highest tertile of agreement and were associated with moderate (n=6) or high consensus (n=27). Statements with similar recommendations were combined, resulting in 27 final guidance statements. CONCLUSION: These guidance statements have been generated based on review of the available literature, indicating that children with PRD do not appear to be at increased risk for susceptibility to SARS‐CoV‐2 infection. This guidance is presented as a “living document,” recognizing that the literature on COVID‐19 is rapidly evolving, with future updates anticipated.
has issue date	2020-07-23(xsd:dateTime)
bibo:doi	10.1002/art.41455
bibo:pmid	32705780
has license	no-cc
sha1sum (hex)	1652d8c3306cfa2c316c6c2eacd86638276113f4
schema:url	https://doi.org/10.1002/art.41455
resource representing a document's title	American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 1
has PubMed Central identifier	PMC7404941
has PubMed identifier	32705780
schema:publication	Arthritis Rheumatol
resource representing a document's body	covid:1652d8c3306cfa2c316c6c2eacd86638276113f4#body_text
is schema:about of	named entity 'Title' named entity 'USED' named entity 'methodology' named entity 'authors' named entity 'Rheumatic Disease' named entity 'immunosuppressive therapy' named entity 'fever' named entity 'COVID-19 pandemic' named entity 'mental health' named entity 'glucocorticoids' named entity 'ICU' named entity 'COVID-19' named entity 'glucocorticoid' named entity 'CDC' named entity 'SARS-CoV-2' named entity 'DMARD' named entity 'RSV' named entity 'serologic testing' named entity 'telemedicine' named entity 'COVID-19' named entity 'juvenile idiopathic arthritis' named entity 'cyclophosphamide' named entity 'PRD' named entity 'COVID-19' named entity 'PRD' named entity 'intra-articular' named entity 'lymphopenia' named entity 'leukopenia' named entity 'COVID-19' named entity 'adrenal suppression' named entity 'glucocorticoids' named entity 'cytokine storm' named entity 'IL-1' named entity 'webinar' named entity 'De-escalation' named entity 'clinical practice' named entity 'PRD' named entity 'ARBs' named entity 'COVID-19 pandemic' named entity 'DMARDs' named entity 'immune dysregulation' named entity 'Glucocorticoids' named entity 'SARS-CoV-2' named entity 'infectious disease' named entity 'glucocorticoids' named entity 'preventative measures' named entity 'influenza season' named entity 'COVID-19' named entity 'glucocorticoids' named entity 'rheumatology' named entity 'IL-6' named entity 'infection' named entity 'non-steroidal anti-inflammatory drugs' named entity 'angiotensin II' named entity 'OSHA' named entity 'glucocorticoids' named entity 'Rheumatology' named entity 'COVID-19' named entity 'cyclophosphamide' named entity 'PRD' named entity 'infection' named entity 'social distancing' named entity 'COVID-19' named entity 'community transmission' named entity 'de-escalation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software